The effect of etoposide on human CFU-GM.
Etoposide is being used increasingly in the treatment of a variety of malignant conditions and in conjunction with autologous bone marrow transplantation. We have examined the effect of the drug on human CFU-GM as an indication of the response of these bone marrow progenitor cells to measured plasma concentrations. When etoposide is present in the routine assay for 7 days, 50% growth of colony-forming CFU-GM occurs at a concentration of 0.0098 micrograms ml-1. When bovine serum albumin or human serum albumin is present this value is increased to 0.042 and 0.375 micrograms ml-1. Protein binding therefore plays an important part in modifying in vitro response and possibly in vivo response of these progenitor cells to etoposide.
D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D005047:Etoposide / Q000494:pharmacology*; D006098:Granulocytes; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D009000:Monocytes; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011485:Protein Binding; D012709:Serum Albumin; D012710:Serum Albumin, Bovine
D012709:Serum Albumin; D012710:Serum Albumin, Bovine; D005047:Etoposide; D011034:Podophyllotoxin